Retinoblastoma (RB) is the most common pediatric intraocular malignancy, with an incidence of roughly 1 in 15,000–20,000 live births. Tumours can compromise vision and metastasize locally along the optic nerve to the central nervous system (CNS) or systemically to bone and lung. Current multimodal therapies (enucleation, chemotherapy, focal treatments) improve globe salvage but are associated with long-term retinal and systemic toxicities, and some tumours develop chemoresistance. There is therefore a clinical need for novel, targeted approaches with improved efficacy and reduced adverse effects.
Transcriptional dysregulation and epigenetic changes are increasingly recognized drivers of RB. Super-enhancers (SEs) are dense clusters of enhancers marked by high occupancy of transcription factors, cofactors, mediator complexes and elevated histone modifications such as H3K27ac and H3K4me1. SEs regulate high-level transcription of genes that control cellular identity and processes including proliferation, survival and stemness. Aberrant SEs have been implicated in multiple cancers, but prior to this study the genome-wide SE landscape and its regulatory mechanisms in RB had not been comprehensively characterized.
To define SEs in RB, the authors profiled active enhancers by chromatin immunoprecipitation sequencing (ChIP-Seq) for H3K27ac and integrated these data with bulk RNA sequencing (RNA-Seq). Single-cell RNA sequencing (scRNA-Seq), qRT-PCR and immunohistochemistry (IHC) were used to evaluate candidate regulators of SE activity in RB cells and clinical specimens. Through these approaches, cyclin-dependent kinase 12 (CDK12) emerged as an overexpressed factor in RB and as a key regulator of oncogenic SE activity. The report frames CDK12 as a transcription-associated cyclin-dependent kinase with context-dependent roles in development and cancer; in RB it functions as a master regulator of SE-driven transcription.
The study tested CDK12 perturbation using both genetic and pharmacologic approaches. Lentiviral shRNAs targeting CDK12 were used to reduce CDK12 expression in RB cell lines. Pharmacologic inhibitors (BSJ-4-116 and CDK12-IN-3) were applied in vitro; both compounds were prepared as 20 mM DMSO stocks. Effects of CDK12 suppression were assessed on SE-driven transcription, cell survival, and stemness markers by RNA analysis and protein assays. CDK12 inhibition reduced SE-associated oncogenic transcription and induced anti-tumour effects in cell-based assays. Specific experimental protocols included Western blotting with antibodies against RNAP II CTD Ser2, total RNAP II, CDK12, and apoptosis and survival markers among others.
Integration of the SE map with bulk RNA-Seq identified SE-associated oncogenes critically involved in RB cell viability and stem-like properties. Two notable SE-linked genes reported were BIRC5 and PTPRC. Functional assays (shRNA knockdown, CRISPR-based enhancer perturbation and overexpression) indicated that both genes are essential for RB proliferation, survival, and maintenance of stemness. Importantly, overexpression of PTPRC was reported to rescue the anti-tumour effects of the CDK12 degrader BSJ-4-116, indicating that at least part of the therapeutic mechanism of CDK12 blockade acts through suppression of downstream SE targets such as PTPRC.
CDK12 inhibition was evaluated in multiple preclinical RB models. The authors report anti-tumour efficacy in subcutaneous xenografts, orthotopic intraocular models, and models of CNS-metastatic RB. Both pharmacological degradation and genetic suppression of CDK12 attenuated tumour outgrowth and metastatic behavior in these models. These preclinical results support the concept that disrupting the CDK12–SE axis can eliminate or markedly reduce RB tumour growth and dissemination in experimental systems.
Key cell lines used were the RB lines Y79 and WERI-Rb1 (from ATCC), SO-Rb50 (established at Zhongshan Ophthalmic Center), the retinal pigment epithelium line ARPE-19 and 293T for lentiviral packaging. Cells were cultured in standard RPMI 1640 or DMEM with 10% FBS, at 37 °C and 5% CO2; DMSO concentrations were maintained below 0.1% (v/v). Lentiviral shRNA constructs targeting CDK12, BIRC5 and PTPRC were cloned into pLKO.1 and used to generate stable knockdown lines following puromycin selection. CRISPRa and CRISPRi systems were employed for enhancer perturbation experiments. Antibodies used for protein detection and the sources of small-molecule inhibitors are detailed in the methods. All cell lines were authenticated by STR and tested negative for mycoplasma according to the reported methods.
The authors define CDK12 as a master regulator of oncogenic super-enhancers in retinoblastoma. CDK12 supports SE-driven transcriptional programs that include critical oncogenes such as BIRC5 and PTPRC, which sustain RB cell proliferation, survival and stemness. Both genetic and pharmacologic suppression of CDK12 disrupted SE activity, reduced expression of SE-associated oncogenes, and produced anti-tumour effects across multiple preclinical RB models, including intraocular and CNS-metastatic settings. The study proposes targeting the CDK12–SE axis, either upstream at CDK12 or downstream at effectors like BIRC5 and PTPRC, as a promising therapeutic strategy for RB.
Note: Specific quantitative results, statistical analyses, and detailed sequencing metrics were not provided in the excerpt of the source article supplied here.